Ownership and insider activity for BriaCell Therapeutics Corp. (BCTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer.
Price
| Price | $4.22 |
| Market Cap | $37M |
| Exchange | NASDAQ |
| Country | CA |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2024-05-14 | Lustig Marc | P-Purchase | 902,935 | $2.0M |
| 2024-05-14 | Lustig Marc | P-Purchase | 902,935 | $1.9M |
| 2022-12-28 | Bondarenko Jamieson | P-Purchase | 28,000 | $128K |
| 2022-12-23 | Williams William V. | P-Purchase | 2,530 | $5K |
| 2022-12-20 | Bondarenko Jamieson | P-Purchase | 22,000 | $118K |
| 2022-08-01 | Bondarenko Jamieson | |||
| 2022-08-01 | Bondarenko Jamieson | 250,000 | $2.1M | |
| 2021-08-12 | Bondarenko Jamieson | 70,000 | $372K | |
| 2021-03-29 | Bondarenko Jamieson | 150,000 | $636K | |
| 2022-08-01 | Lustig Marc |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $131576 | $1.0M | $720259 | $157034 | $21249 | $71.6M | $52.6M | $28.4M | $1.2M | $14.4M |
| Short-term Investments | $689021 | $601757 | $1.0M | 0 | 0 | 0 | 0 | 0 | 0 | $10.1M |
| Receivables | $2669 | $5601 | $14563 | $2816 | $22515 | $15714 | $30911 | $958562 | $1.9M | $776542 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $833345 | $1.6M | $1.9M | $168533 | $261463 | $72.2M | $54.3M | $36.0M | $5.1M | $27.4M |
| Property, Plant & Equipment | $449 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $538872 | $408099 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | $274733 | $276121 | $260866 | $306954 | $295404 | $287228 | $277360 | $253705 |
| Total Assets | $835696 | $1.6M | $2.3M | $444656 | $522331 | $72.5M | $54.6M | $36.3M | $8.2M | $29.8M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | $267594 | $594145 | $1.5M | $10.0M | $4.5M |
| Short-term Debt | 0 | 0 | $1.1M | $322526 | $249799 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $48591 | $885904 | $1.3M | $1.1M | $4.0M | $695862 | $1.2M | $2.4M | $10.4M | $5.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $32476 | 0 | 0 | 0 | 0 |
| Total Liabilities | $48591 | $885904 | $1.3M | $1.1M | $4.1M | $38.0M | $41.4M | $41.3M | $11.9M | $5.9M |
| Retained Earnings | -$4.3M | -$6.7M | -$9.7M | -$14.7M | -$18.2M | -$36.4M | -$77.4M | -$107.7M | -$118.6M | -$153.7M |
| Total Equity | $787105 | $750232 | $945016 | -$688665 | -$3.6M | $34.6M | $13.2M | -$5.0M | -$3.3M | $24.6M |
| Total Debt | 0 | 0 | $1.1M | $322526 | $249799 | $32476 | 0 | 0 | 0 | 0 |
| Net Debt | -$820597 | -$1.6M | -$628854 | $165492 | $228550 | -$71.5M | -$52.6M | -$28.4M | -$1.2M | -$24.6M |
| Working Capital | $784754 | $748327 | $537519 | -$964788 | -$3.7M | $71.5M | $53.1M | $33.6M | -$5.3M | $21.9M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 7.07 |
Profitability
| Return on Equity | -147.92% |
| Return on Invested Capital | -136.31% |
| Return on Assets | -113.23% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALLR · ASBP · CRIS · CTXR · ENTO · HOTH · LPTX
Explore sector: Healthcare · Biotechnology
More sections of BCTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks